Raquel C.
- Country
- Spain
- Department
- Medical oncology
Research Overview
- Phase 3 Randomized Study of Adagrasib Versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
- Phase II Evaluation of Repotrectinib Efficacy and Safety in ROS1-Positive NSCLC Patients with Active Brain Metastases
- Phase 3 Randomized Open-Label Trial of OSE2101 Versus Docetaxel in HLA-A2 Positive Metastatic NSCLC Patients with Secondary Resistance to Immune Checkpoint Inhibitors
Data & Insights
Has run more than one trial at 44 of 181 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating non-small cell lung cancer (NSCLC), with particular emphasis on cases involving specific molecular characteristics such as ROS1-positive mutations.
- Advanced Lung Cancer Management
- Molecular-Targeted Therapies
- Precision Medicine Approaches
Their work demonstrates expertise in personalized treatment strategies for lung cancer patients.
Neuro-Oncology Expertise
The investigator has developed significant expertise in treating brain metastases in cancer patients, focusing on the complex challenges of central nervous system involvement in lung cancer.
- Brain Metastasis Treatment
- CNS-Directed Therapies
- Intracranial Response Assessment
Their research encompasses comprehensive approaches to managing neurological complications in cancer patients.
Treatment Innovation
The investigator explores novel therapeutic approaches for patients with advanced thoracic malignancies, particularly focusing on targeted treatment strategies.
- Novel Therapeutic Agents
- Biomarker-Driven Treatment
- Clinical Efficacy Assessment
Their work contributes to advancing treatment options for patients with complex oncological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.